Business Context and Reporting Period
Cytosorbents Corporation (CTSO), a Delaware corporation, filed this Form 8-K on April 1, 2026. The report addresses a material event regarding the company's continued listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary material change is the receipt of an extension from Nasdaq to regain compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)).
- Previous Status: On October 2, 2025, the company was notified of non-compliance due to a closing bid price below $1.00 for 30 consecutive trading days.
- Initial Deadline: The initial 180-day compliance period was set to expire on March 31, 2026.
- Current Status: On April 1, 2026, Nasdaq granted a second 180-day extension.
- New Deadline: The company now has until September 28, 2026, to regain compliance.
Outlook, Management Commentary, and Risks
Management intends to actively monitor the bid price and consider available options to resolve the deficiency, including effecting a reverse stock split if necessary.
- Compliance Criteria: To regain compliance, the common stock must close at $1.00 per share or more for a minimum of 10 consecutive trading days prior to September 28, 2026.
- Risks: There is no assurance that the company will regain compliance during the extension period. Failure to do so may result in the delisting of the common stock from Nasdaq.
- Immediate Impact: The extension notice has no immediate effect on the listing of the stock or the company's SEC reporting requirements.
Investor Verification Checklist
- Verify the current closing bid price of CTSO common stock relative to the $1.00 threshold.
- Monitor for any future announcements regarding a reverse stock split or other capital structure changes.
- Track the stock's performance to ensure it meets the 10 consecutive trading day requirement before the September 28, 2026 deadline.
- Review the company's most recent 10-K or 10-Q filings for underlying financial performance data not included in this 8-K.